Benign tumors form when cells grow faster than normal but, unlike cancer, don’t invade nearby tissue or spread to other parts of the body. The underlying causes range from genetic glitches and hormonal shifts to chronic inflammation and viral infections. In most cases, the trigger is a breakdown in the body’s built-in system for controlling when cells divide and when they stop.
How Normal Cell Growth Goes Wrong
Your body has an elaborate system of checks that controls when a cell can copy itself and when it should stop or self-destruct. Two key protein families, called cyclins and cyclin-dependent kinases, act like a relay team that passes signals forward through each stage of cell division. When either of these proteins malfunctions, the downstream safety signals don’t fire correctly, and cells can keep dividing when they shouldn’t.
The most important safety mechanism is a protein called p53, often described as the “guardian of the genome.” When DNA gets damaged, p53 activates repair crews, halts cell division until the damage is fixed, and, if the damage is too severe, triggers the cell to destroy itself. It also switches on a cascade of helper proteins that block cells from progressing through division. When p53 or any of these helper proteins stop working properly, damaged cells survive and accumulate into a mass of tissue: a tumor.
Your cells also run a constant spell-check on DNA as it’s being copied. A group of seven mismatch repair proteins scans for errors in the genetic code and pauses division until they’re corrected. Separate proteins detect breaks in both strands of DNA, often caused by ultraviolet light, and halt everything until the break is repaired using the matching chromosome as a template. A failure at any of these checkpoints allows mutations to persist and pass to daughter cells, gradually building a population of cells that grows beyond normal limits.
What keeps a benign tumor benign is that these errors are limited. Enough of the cell’s regulatory machinery still works to prevent the tumor from becoming aggressive. The cells pile up in one location but retain enough normal behavior that they don’t break through tissue boundaries or enter the bloodstream.
Genetic Mutations and Inherited Conditions
Many benign tumors are driven by the same genetic mutations found in cancers, just fewer of them at once. Mutations in genes like BRAF, RAS, PTEN, and NF1/2 appear in benign and premalignant growths, sometimes at even higher rates than in their malignant counterparts. The critical difference is that a single “driver” mutation often triggers a self-limiting response. For example, a BRAF mutation in a mole can push cells to divide briefly, but the cells then enter a state of permanent growth arrest called senescence. It typically takes additional mutations, such as the loss of PTEN or another tumor suppressor, to override that arrest and push the growth toward cancer.
Some people inherit mutations that make benign tumors far more likely. Neurofibromatosis type 1 is caused by inherited mutations in the NF1 gene, which normally keeps a growth-signaling pathway in check. Without functional NF1, that pathway stays hyperactive, leading to benign nerve tumors called neurofibromas that grow on or under the skin. Most cutaneous neurofibromas remain benign and never transform into cancer, though deeper plexiform neurofibromas can sometimes become aggressive.
Neurofibromatosis type 2 involves a different gene that produces a protein called merlin, another tumor suppressor. Inherited mutations here lead to benign tumors of the nerve sheath, particularly vestibular schwannomas (growths on the hearing and balance nerve), meningiomas, and low-grade brain tumors. In both conditions, the inherited mutation removes one layer of protection, and a second hit to the remaining copy of the gene in a specific cell is enough to start a benign growth.
Hormones and Tumor Growth
Uterine fibroids are one of the clearest examples of hormone-driven benign tumors. These smooth-muscle growths in the uterus are considered estrogen-dependent: they never appear before puberty, and they typically shrink after menopause when estrogen levels drop. Treatments that suppress ovarian estrogen production also cause fibroids to regress.
The relationship is more nuanced than simple estrogen exposure, though. Women with fibroids and women without them have similar estrogen levels in their blood. The difference is local: fibroid tissue produces its own estrogen through an enzyme called aromatase, creating higher hormone concentrations right where the tumor sits. Estrogen’s main role appears to be priming fibroid cells to respond to progesterone, the other major reproductive hormone. Research using animal models has shown that estrogen creates the microenvironment in which progesterone then drives actual fibroid growth. This is why fibroids often enlarge during pregnancy, when both hormones surge, and why hormonal therapies that target this interplay can be effective at controlling them.
Hormonal influence extends beyond fibroids. Thyroid adenomas, certain types of breast lumps, and some pituitary tumors also respond to hormonal signals, growing or shrinking as hormone levels change through life stages like puberty, pregnancy, and menopause.
Chronic Inflammation and Tissue Injury
When tissue is injured repeatedly or stays inflamed for a long time, the constant cycle of damage and repair can push cells toward abnormal growth. Chronic irritation forces cells to divide over and over to replace damaged tissue. Each round of division is another opportunity for copying errors in DNA to slip through. Over time, this increased cell turnover and the accumulation of small mutations can produce a benign growth.
The inflammatory process itself contributes directly. Immune cells drawn to the site release signaling molecules called cytokines, which activate still more immune cells and stimulate tissue remodeling. Some of these signals trigger specialized cells to deposit excess collagen, which is part of what happens in keloids, the raised, overgrown scars that form at wound sites in some people. Reactive oxygen species, the chemically aggressive molecules that immune cells use to fight pathogens, also damage DNA in bystander cells. That accumulation of DNA damage in a chronically inflamed area creates fertile ground for abnormal cell populations to take hold.
Viral Infections
Common warts are benign tumors caused by human papillomavirus (HPV). The virus enters the skin through tiny cuts or abrasions and infects the basal layer of the epidermis, the deepest layer of skin cells. Once inside, HPV hijacks the cell’s growth controls using two viral proteins, E6 and E7.
The E6 protein targets p53, the cell’s main tumor suppressor, and marks it for destruction. Without p53, cells with DNA damage survive instead of self-destructing. Meanwhile, E7 disables another tumor suppressor called Rb, which normally acts as a gatekeeper for cell division. With Rb deactivated, the cell’s division machinery runs unchecked. Together, these two proteins push infected skin cells into rapid proliferation, expanding the pool of cells the virus can use to replicate. The result is the thickened, raised skin growth we recognize as a wart. Because the virus drives proliferation without the additional mutations needed for invasion, most HPV-caused skin lesions stay benign.
Metabolic Factors and Body Weight
Insulin resistance and obesity create a hormonal environment that favors cell growth. When the body becomes less responsive to insulin, both insulin and a related hormone called insulin-like growth factor 1 (IGF-1) circulate at higher levels. These elevated levels stimulate cell proliferation and suppress apoptosis, the normal process by which the body clears out old or damaged cells.
High insulin and IGF-1 levels are associated with an increased risk of colorectal adenomas, the benign polyps that grow in the lining of the colon. These adenomas are particularly important because some can progress to colon cancer over time. While insulin and IGF-1 signaling alone don’t appear to flip the switch from benign to malignant, they create what researchers describe as a “permissive environment,” one where other mutations are more likely to take hold and push growth forward.
Radiation Exposure
Radiation damages DNA directly, and the resulting mutations can seed benign growths years or even decades later. Data from long-term follow-up of childhood cancer survivors illustrates this clearly. Among nearly 6,000 survivors tracked for a median of over 22 years, those who received radiation therapy had the highest rates of subsequent benign tumors. By age 30, roughly 17% of those treated with radiation alone had developed a benign tumor, compared to 4 to 6% for those treated with other methods or for their unaffected siblings. By age 45, about one in four female survivors and one in six male survivors had developed a benign growth. Adenomas were among the most common types found in this population.
The long lag between exposure and tumor development reflects how radiation works at the cellular level. It doesn’t create a tumor immediately. Instead, it damages DNA in ways that may not cause problems until a cell divides years later and the flawed repair finally produces a growth-promoting mutation.
Why Most Benign Tumors Stay Benign
Cancer typically requires a stack of multiple mutations, each disabling a different layer of the cell’s defense system. A benign tumor usually has one or a few of these mutations, enough to cause excess growth but not enough to give cells the ability to invade tissue, recruit their own blood supply, or metastasize. The body’s remaining safeguards, particularly oncogene-induced senescence, where a single strong growth signal actually triggers cells to permanently stop dividing, act as a firewall. For a benign growth to become malignant, additional mutations must knock out these backup systems one by one. In most benign tumors, that never happens.